Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Radiation Oncology
Published in: Journal of Radiation Oncology 2/2019

Open Access 01-06-2019 | NSCLC | Correction

Correction to: Stereotactic body radiation therapy for non-small cell lung cancer patients with prior history of thoracic surgery and/or radiation therapy: the influence of smoking, size, and central location on risk of complications

Authors: Jason W. Chan, Julian Johnson, Ann A. Lazar, Steve E. Braunstein, Martina Descovich, Alexander R. Gottschalk, Sue S. Yom

Published in: Journal of Radiation Oncology | Issue 2/2019

Login to get access

Excerpt

Correction to: Journal of Radiation Oncology (2018) 7:53–61 …
Metadata
Title
Correction to: Stereotactic body radiation therapy for non-small cell lung cancer patients with prior history of thoracic surgery and/or radiation therapy: the influence of smoking, size, and central location on risk of complications
Authors
Jason W. Chan
Julian Johnson
Ann A. Lazar
Steve E. Braunstein
Martina Descovich
Alexander R. Gottschalk
Sue S. Yom
Publication date
01-06-2019
Publisher
Springer Berlin Heidelberg
Keywords
NSCLC
NSCLC
Published in
Journal of Radiation Oncology / Issue 2/2019
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-019-00377-z

Other articles of this Issue 2/2019

Journal of Radiation Oncology 2/2019 Go to the issue

Original Research

Lymphopenia as a predictor of survival in chemoradiation-treated stage III non-small-cell lung cancer (NSCLC): a multi-center retrospective analysis

Original Research

Changes in prostate-specific antigen midway through salvage radiotherapy may be associated with long-term outcomes

Original Research

Quantitative assessment of the efficacy of two different treatment plan optimization algorithms in treating tumors in locations of high heterogeneity

Abstracts

THE PROCEEDINGS OF THE RADIATION ONCOLOGY SUMMIT: ACRO 2019

Original Research

Adjuvant chemoradiation in resected gallbladder cancer: a prognostic index model for predicting overall survival

Original Research

Neoadjuvant chemotherapy and high-dose radiation using intensity-modulated radiotherapy followed by rectal sparing TEM for distal rectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits